These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

631 related articles for article (PubMed ID: 33070624)

  • 41. Cost-effectiveness of Sacituzumab Govitecan versus Single-agent Chemotherapy for Patients with Metastatic Triple-Negative Breast Cancer in China.
    Wang L; Liu L; Zhang Z; Li F; Ruan Y; He Y; Huang J; Zheng X
    Clin Breast Cancer; 2024 Oct; 24(7):e545-e553.e6. PubMed ID: 38760263
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sacituzumab govitecan (Trodelvy) for metastatic triple-negative breast cancer.
    Med Lett Drugs Ther; 2021 Feb; 63(1617):e25-e27. PubMed ID: 33757114
    [No Abstract]   [Full Text] [Related]  

  • 43. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC).
    Goldenberg DM; Cardillo TM; Govindan SV; Rossi EA; Sharkey RM
    Oncotarget; 2015 Sep; 6(26):22496-512. PubMed ID: 26101915
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.
    Bardia A; Rugo HS; Tolaney SM; Loirat D; Punie K; Oliveira M; Brufsky A; Kalinsky K; Cortés J; Shaughnessy JO; Diéras V; Carey LA; Gianni L; Piccart-Gebhart M; Loibl S; Yoon OK; Pan Y; Hofsess S; Phan SC; Hurvitz SA
    J Clin Oncol; 2024 May; 42(15):1738-1744. PubMed ID: 38422473
    [No Abstract]   [Full Text] [Related]  

  • 45. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
    Han C; Perrone E; Zeybek B; Bellone S; Tymon-Rosario J; Altwerger G; Menderes G; Feinberg J; Haines K; Muller Karger ME; Bianchi A; Zammataro L; Manzano A; Bonazzoli E; Manara P; Buza N; Hui P; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Lopez S; Santin AD
    Gynecol Oncol; 2020 Feb; 156(2):430-438. PubMed ID: 31839338
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Summary of quality of life in the ASCENT phase 3 clinical trial for people with metastatic triple-negative breast cancer.
    Loibl S; Loirat D; Tolaney SM; Punie K; Dieras V; Carey LA; Gianni L; Shah A; Phan S; Shi L; Spears PA; Piccart MJ
    Future Oncol; 2024; 20(34):2609-2616. PubMed ID: 39324726
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sacituzumab govitecan: an antibody-drug conjugate.
    Sahota S; Vahdat LT
    Expert Opin Biol Ther; 2017 Aug; 17(8):1027-1031. PubMed ID: 28503956
    [TBL] [Abstract][Full Text] [Related]  

  • 48. TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer.
    Rugo HS; Bardia A; Tolaney SM; Arteaga C; Cortes J; Sohn J; Marmé F; Hong Q; Delaney RJ; Hafeez A; André F; Schmid P
    Future Oncol; 2020 Apr; 16(12):705-715. PubMed ID: 32223649
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sacituzumab govitecan-hziy for triple-negative breast cancer.
    Stirrups R
    Lancet Oncol; 2019 Apr; 20(4):e194. PubMed ID: 30827748
    [No Abstract]   [Full Text] [Related]  

  • 50. Sacituzumab govitecan for hormone receptor-positive and triple-negative breast cancers.
    Satti SA; Sheikh MS
    Mol Cell Pharmacol; 2023; 15(1):1-5. PubMed ID: 37090944
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany.
    Reinisch M; Bruzas S; Spoenlein J; Shenoy S; Traut A; Harrach H; Chiari O; Cremer E; Ataseven B; Gubelt L; Kuemmel S
    Ther Adv Med Oncol; 2023; 15():17588359231200454. PubMed ID: 37789989
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients with Breast Cancer.
    Bardia A; Sun S; Thimmiah N; Coates JT; Wu B; Abelman RO; Spring L; Moy B; Ryan P; Melkonyan MN; Partridge A; Juric D; Peppercorn J; Parsons H; Wander SA; Attaya V; Lormil B; Shellock M; Nagayama A; Bossuyt V; Isakoff SJ; Tolaney SM; Ellisen LW
    Clin Cancer Res; 2024 Jul; 30(14):2917-2924. PubMed ID: 38709212
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan.
    McGuinness JE; Kalinsky K
    Expert Opin Biol Ther; 2021 Jul; 21(7):903-913. PubMed ID: 33089726
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An ADC for Triple-Negative Breast Cancer.
    Cancer Discov; 2016 Jan; 6(1):OF8. PubMed ID: 26577300
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer.
    Xie J; Li S; Li Y; Li J
    BMC Health Serv Res; 2023 Jun; 23(1):706. PubMed ID: 37386633
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo.
    Perrone E; Manara P; Lopez S; Bellone S; Bonazzoli E; Manzano A; Zammataro L; Bianchi A; Zeybek B; Buza N; Tymon-Rosario J; Altwerger G; Han C; Menderes G; Huang GS; Ratner E; Silasi DA; Azodi M; Hui P; Schwartz PE; Scambia G; Santin AD
    Mol Oncol; 2020 Mar; 14(3):645-656. PubMed ID: 31891442
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer.
    Manna M; Brabant M; Greene R; Chamberlain MD; Kumar A; Alimohamed N; Brezden-Masley C
    Curr Oncol; 2024 Sep; 31(9):5694-5708. PubMed ID: 39330050
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [New drug approval: Sacituzumab govitecan in third line in advanced or metastatic triple-negative breast cancer].
    Kabirian R; Da Silva A
    Bull Cancer; 2022 Mar; 109(3):249-250. PubMed ID: 35094841
    [No Abstract]   [Full Text] [Related]  

  • 59. ADC Could Benefit Some with Breast Cancer.
    Cancer Discov; 2019 May; 9(5):570. PubMed ID: 30867160
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer.
    Cheng SX; Chen QC; Lin GH; Han YH; Wang BC; Dai Y; Zhao YX
    Medicine (Baltimore); 2023 Jul; 102(30):e34486. PubMed ID: 37505137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.